A citation-based method for searching scientific literature


List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.
L-Y Huw, C O'Brien, A Pandita, S Mohan, J M Spoerke, S Lu, Y Wang, G M Hampton, T R Wilson, M R Lackner. Oncogenesis 2013
60
100


PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer.
Ilenia Migliaccio, Marta Paoli, Emanuela Risi, Chiara Biagioni, Laura Biganzoli, Matteo Benelli, Luca Malorni. NPJ Breast Cancer 2022
1
100

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Mario Giuliano, Huizhong Hu, Yen-Chao Wang, Xiaoyong Fu, Agostina Nardone, Sabrina Herrera, Sufeng Mao, Alejandro Contreras, Carolina Gutierrez, Tao Wang,[...]. Clin Cancer Res 2015
64
100

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
M Cizkova, M-E Dujaric, J Lehmann-Che, V Scott, O Tembo, B Asselain, J-Y Pierga, M Marty, P de Cremoux, F Spyratos,[...]. Br J Cancer 2013
69
100

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
Sarika Jain, Ami N Shah, Cesar A Santa-Maria, Kalliopi Siziopikou, Alfred Rademaker, Irene Helenowski, Massimo Cristofanilli, William J Gradishar. Breast Cancer Res Treat 2018
70
100

PI3K inhibitors: review and new strategies.
Mingzhen Zhang, Hyunbum Jang, Ruth Nussinov. Chem Sci 2020
58
100

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Sherene Loi, Stefan Michiels, Diether Lambrechts, Debora Fumagalli, Bart Claes, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, Vesa Kataja, Martine J Piccart, Heikki Joensuu,[...]. J Natl Cancer Inst 2013
105
100

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Mothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, Fresia Pareja, Felipe C Geyer, Kathleen A Burke, Sabrina Herrera, Tao Wang, Ingrid A Mayer, Andres Forero,[...]. Breast Cancer Res Treat 2018
52
100

The PI3K Pathway in Human Disease.
David A Fruman, Honyin Chiu, Benjamin D Hopkins, Shubha Bagrodia, Lewis C Cantley, Robert T Abraham. Cell 2017
100

Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Cristina Saura, Johanna Bendell, Guy Jerusalem, Shaun Su, Qinhua Ru, Stefan De Buck, David Mills, Sophie Ruquet, Ana Bosch, Ander Urruticoechea,[...]. Clin Cancer Res 2014
102
100

Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Guojun Wu, Mingzhao Xing, Elizabeth Mambo, Xin Huang, Junwei Liu, Zhongmin Guo, Aditi Chatterjee, David Goldenberg, Susanne M Gollin, Saraswati Sukumar,[...]. Breast Cancer Res 2005
173
100

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
583
100

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.
Jeffrey A Engelman, Ji Luo, Lewis C Cantley. Nat Rev Genet 2006
100

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Yan Xing, Nancy U Lin, Matthew A Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton,[...]. Breast Cancer Res 2019
91
100

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Brian D Lehmann, Joshua A Bauer, Johanna M Schafer, Christopher S Pendleton, Luojia Tang, Kimberly C Johnson, Xi Chen, Justin M Balko, Henry Gómez, Carlos L Arteaga,[...]. Breast Cancer Res 2014
208
100

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Ana C Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré,[...]. Breast Cancer Res 2020
34
100

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret, Jihane Pakradouni, Magali Provansal, Jacques Camerlo, Renaud Sabatier, François Bertucci,[...]. Eur J Cancer 2017
34
100

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.
Katherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, Patrick G Gavin, Seong-Rim Kim, Nicole L Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas,[...]. J Clin Oncol 2015
84
100

Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors.
Anna Thulin, Carola Andersson, Elisabeth Werner Rönnerman, Shahin De Lara, Chaido Chamalidou, Arnd Schoenfeld, Anikó Kovács, Henrik Fagman, Fredrik Enlund, Barbro K Linderholm. Sci Rep 2021
2
100

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
Huayu Hu, Junyong Zhu, Yuting Zhong, Rui Geng, Yashuang Ji, Qingyu Guan, Chenyan Hong, Yufan Wei, Ningning Min, Aiying Qi,[...]. Ann Transl Med 2021
13
100

PI3K inhibitors are finally coming of age.
Bart Vanhaesebroeck, Matthew W D Perry, Jennifer R Brown, Fabrice André, Klaus Okkenhaug. Nat Rev Drug Discov 2021
81
100

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Valentina Guarneri, Antonio Frassoldati, Alberto Bottini, Katia Cagossi, Giancarlo Bisagni, Samanta Sarti, Alberto Ravaioli, Luigi Cavanna, Giovanni Giardina, Antonino Musolino,[...]. J Clin Oncol 2012
263
100

Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, Luca Gianni. Nat Rev Clin Oncol 2022
96
100

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
Ana M Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, Aysegul Sahin, Shuying Liu, Juan A Barrera, Octavio Burgues, Ana M Lluch, Huiqin Chen, Gabriel N Hortobagyi,[...]. Mol Cancer Ther 2011
183
100

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
U A Matulonis, G M Wulf, W T Barry, M Birrer, S N Westin, S Farooq, K M Bell-McGuinn, E Obermayer, C Whalen, T Spagnoletti,[...]. Ann Oncol 2017
136
100

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
M Martín, A Chan, L Dirix, J O'Shaughnessy, R Hegg, A Manikhas, M Shtivelband, P Krivorotko, N Batista López, M Campone,[...]. Ann Oncol 2017
108
100

PI3K/AKT signaling pathway and cancer: an updated review.
Miriam Martini, Maria Chiara De Santis, Laura Braccini, Federico Gulluni, Emilio Hirsch. Ann Med 2014
690
100

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
B Pistilli, T Pluard, A Urruticoechea, D Farci, A Kong, T Bachelot, S Chan, H S Han, G Jerusalem, P Urban,[...]. Breast Cancer Res Treat 2018
32
100

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Fabrice André, Sara Hurvitz, Angelica Fasolo, Ling-Ming Tseng, Guy Jerusalem, Sharon Wilks, Ruth O'Regan, Claudine Isaacs, Masakazu Toi, Howard Burris,[...]. J Clin Oncol 2016
116
100

Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
Willemijne A M E Schrijver, Karijn P M Suijkerbuijk, Carla H van Gils, Elsken van der Wall, Cathy B Moelans, Paul J van Diest. J Natl Cancer Inst 2018
115
100

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
José Baselga, Gail D Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E Guardino, Meghna K Samant, Steve Olsen, Sanne L de Haas, Mark D Pegram. Clin Cancer Res 2016
128
100

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
F Mosele, B Stefanovska, A Lusque, A Tran Dien, I Garberis, N Droin, C Le Tourneau, M-P Sablin, L Lacroix, D Enrico,[...]. Ann Oncol 2020
84
100

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.
Romualdo Barroso-Sousa, Tanya E Keenan, Sonia Pernas, Pedro Exman, Esha Jain, Ana C Garrido-Castro, Melissa Hughes, Brittany Bychkovsky, Renato Umeton, Janet L Files,[...]. Clin Cancer Res 2020
85
100

Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer.
Lu Yang, Ning Li, Zhicheng Xue, Ling-Rui Liu, Jian Li, Xiaojia Huang, Xinhua Xie, Yutian Zou, Hailin Tang, Xiaoming Xie. Cell Death Differ 2020
16
100

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Michael Untch, Mahdi Rezai, Sibylle Loibl, Peter A Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, Jörn Hilfrich, Holger Eidtmann, Bernd Gerber,[...]. J Clin Oncol 2010
374
100

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Yuichi Ando, Megumi Inada-Inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt,[...]. Cancer Sci 2014
67
100

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T Ueno, Aleix Prat, Yee Soo Chae,[...]. N Engl J Med 2022
114
100

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Michael Untch, Sibylle Loibl, Joachim Bischoff, Holger Eidtmann, Manfred Kaufmann, Jens-Uwe Blohmer, Jörn Hilfrich, Dirk Strumberg, Peter A Fasching, Rolf Kreienberg,[...]. Lancet Oncol 2012
306
100

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Katrien Berns, Hugo M Horlings, Bryan T Hennessy, Mandy Madiredjo, E Marielle Hijmans, Karin Beelen, Sabine C Linn, Ana Maria Gonzalez-Angulo, Katherine Stemke-Hale, Michael Hauptmann,[...]. Cancer Cell 2007
100

PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Aryana R Rasti, Amy Guimaraes-Young, Farrah Datko, Virginia F Borges, Dara L Aisner, Elena Shagisultanova. JCO Precis Oncol 2022
2
100

Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
C Elfgen, K Reeve, L Moskovszky, U Güth, V Bjelic-Radisic, M Fleisch, C Tausch, Z Varga. J Cancer Res Clin Oncol 2019
12
100

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Ashish Juvekar, Laura N Burga, Hai Hu, Elaine P Lunsford, Yasir H Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A Lyssiotis,[...]. Cancer Discov 2012
309
100


PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
V Serra, M Scaltriti, L Prudkin, P J A Eichhorn, Y H Ibrahim, S Chandarlapaty, B Markman, O Rodriguez, M Guzman, S Rodriguez,[...]. Oncogene 2011
402
100




Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku, Timothy A Yap, Funda Meric-Bernstam. Nat Rev Clin Oncol 2018
545
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.